Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

North Carolina Residents Should Urge Lawmakers To Continue Funding HIV Program, Opinion Piece Says
The North Carolina legislature has proposed to eliminate the HIV Medicaid Case Management program, which "provides crucial support to people living with HIV, helping them access medical care, medications and the support services needed to live healthier lives," Jacquelyn Clymore of the Alliance of AIDS Services-Carolina and Beth Stringfield, member of the North Carolina AIDS Action Network, write in a Durham News opinion piece, adding, "We need to call legislators and let them know how important this program is to those living with HIV and ask them to return the program and its funding to the budget." They continue, "It is likely that additional budget cuts to HIV programs will be proposed, and we must speak out in support of state HIV prevention funding" (Clymore/Stringfield, Durham News, 6/13).
generic viagra online
Controling Concurrent Hepatitis B Infection By Focusing HIV Treatment
Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.
News of the day
National Institutes Of Health Announces New Program To Develop Therapeutics For Rare And Neglected Diseases
The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.
Public Health

StemCells, Inc. To Present Phase I Clinical Trial Results At The 12th International Congress On NCL

StemCells, Inc. (NASDAQ:STEM) announced plans to present data from its Phase I clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) at the 12th International Congress on Neuronal Ceroid Lipofuscinoses (NCL) being held June 3 - 6, 2009 in Hamburg, Germany. Stephen Huhn, MD, FACS, FAAP, vice president and head of the Company"s CNS program, is scheduled to present the data on Saturday, June 6. The six-patient Phase I trial, conducted at Oregon Health & Science University Doernbecher Children"s Hospital, was designed primarily to assess the safety associated with transplanting HuCNS-SC cells as a treatment for infantile and late infantile NCL, often referred to as Batten disease. About Neuronal Ceroid Lipofuscinosis (Batten Disease) Neuronal ceroid lipofuscinosis is a fatal neurodegenerative disorder that afflicts infants and young children. The disorder is caused by genetic mutations, and children who inherit the defective gene are unable to produce enough of an enzyme that processes cellular waste substances that accumulate in a part of cells known as the lysosome. Without the enzyme, the cellular waste builds up, and eventually the cells cannot function and die. Children with NCL appear healthy when born, but as their brain cells die, they begin to suffer seizures and progressively lose motor skills, sight and mental capacity. Eventually, these children become blind, bedridden and unable to communicate or function on their own. There currently is no cure for the disease. The infantile and late infantile forms of NCL are caused by different genetic mutations. As the names imply, the two forms begin to afflict patients at different stages of infancy, but both have similar disease progression and outcomes. About HuCNS-SC® Cells StemCells" lead product candidate, HuCNS-SC cells, is a purified composition of normal human neural stem cells that are expanded and stored as banks of cells. The Company"s preclinical research has shown that HuCNS-SC cells can be directly transplanted; they engraft, migrate, differentiate into neurons and glial cells; and they survive for as long as one year with no sign of tumor formation or adverse effects. These findings show that HuCNS-SC cells, when transplanted, act like normal stem cells, suggesting the possibility of a continual replenishment of normal human neural cells. StemCells, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009